Boston's Lotus soon to bear EU fruit
This article was originally published in Clinica
Executive Summary
CE marking of Boston Scientific’s transcatheter aortic valve implantation (TAVI) contender, Lotus, could be imminent, Clinica understands. While the official line is that it will get the go-ahead in Europe within the next quarter, approval could come as early as in the next few weeks, according to sources close to the matter.